Abstract
The aim of this study is to provide a feedback control, called the Chemotherapy Protocol Law, with the purpose to keep the density of tumor cells that are treated by chemotherapy below a “tolerance level” \(L_c\), while retaining the density of normal cells above a “healthy level” \(N_c\). The mathematical model is a controlled dynamical system involving three nonlinear differential equations, based on a Gompertzian law of cell growth. By evoking viability and set-valued theories, we derive sufficient conditions for the existence of a Chemotherapy Protocol Law. Thereafter, on a suitable viability domain, we build a multifunction whose selections are the required Chemotherapy Protocol Laws. Finally, we propose a design of selection that generates a Chemotherapy Protocol Law.
Similar content being viewed by others
References
Afenya EK, Caldron CP (1996) A brief look at a normal cell decline and inhibition in acute leukemia. J Cancer Detect Prev 20(3):171–179
Alberts B, Johson A, Lewis J, Raff M, Robert K, Walter P (2002) Molecular biology of the cell, 4th edn. Garland Science, New York
Aubin JP (1990) Viability theory. Birkhäuser, Boston
Aubin JP, Frankowska H (1990) Set-valued analysis. Birkhäuser, Boston
Baudino B, D’agata F, Caroppo P, Castellano G, Cauda S, Manfredi M, Geda E, Castelli L, Mortara P, Orsi L, Cauda F, Sacco K, Ardito RB, Pinessi L, Geminiani G, Torta R, Bisi G (2012) The chemotherapy long-term effect on cognitive functions and brain metabolism in lymphoma patients. Q J Nucl Med Mol Imaging 56(6):559–568
Bratus A, Fimmel AS, Todorov Y, Semenov Y, Nuernberg YS (2012) On strategies on a mathematical model for leukemia therapy. J Nonlinear Anal Real World Appl 13:1044–1059
Bratus A, Todorov Y, Yegorov I, Yurchenko D (2013) Solution of the feedback control problem in the mathematical model of leukemia therapy. J Optim Theory Appl 159:590–605
Bratus A, Yegorov I, Yurchenko D (2016) Dynamic mathematical models of therapy processes against glioma and leukemia under stochastic uncertainties. Meccanica dei Materiali e delle Strutture 6(1):131–138
Dexter DL, Leith JT (1986) Tumor heterogeneity and drug resistance. J Clin Oncol 4(3):244–257
Evan GI, Vousden KH (2001) Progress proliferation, cell cycle and apoptosis in cancer. Nature 411:342–348
Gewirtz DA, Holt SE, Grant S (2007) Apoptosis, senescence and cancer. Humana Press, New York
Hoffbrand AV, Petit JE (1984) Essential haematology. Blackwell, Oxford
Isaeva OG, Ospove VA (2009) Different strategies for cancer treatment : mathematical modeling. J Comput Math Methods Med 10:253–272
Kassara K (2006) A set-valued approach to control immunotherapy. J Math Comput Model 44:1114–1125
Kassara K (2009) A unified set-valued approach to control immunotherapy. SIAM J Control Optim 48:909–924
Kassara K, Moustafid A (2011) Angiogenesis inhibition and tumor-immune interactions with chemotherapy by a control set-valued method. J Math Biosci 231:135–143
Lasley I (2011) 21st Century cancer treatement. CreateSpace Independent Publishing Platform, Scotts Valley
Matsuda T, Takayama T, Tashiro M, Nakamura Y, Ohashi Y, Shimozuma K (2005) Mild cognitive impairment after adjuvant chemotherapy in breast cancer patients-evaluation of appropriate research design and methodology to measure symptoms. Breast Cancer 12(3):279–287
Matveev AS, Savkin AV (2008) Application of optimal control theory to analysis of cancer chemotherapy regimens. Syst Control Lett 46(5):4042–4048
Ness KK, Gurney JG (2007) Adverse late effects of childhood cancer and its treatment on health and performance. Annu Rev Public Health 28:278–302
Nowell PC (2002) Tumour progression: a brief historical perspective. Semin Cancer Biol 12:261–266
Riah R, Fiacchini M, Alamir M (2015) Invariance-based analysis of cancer chemotherapy. IEEE conference on control application (CCA), pp 1111–1116
Rubinow SI, Lebowitz JL (1976) A mathemathecal model of the acute myeloblastic leukemic state in man. Biophys J 16:897–910
Schimke RT (1984) Gene amplification, drug resistance and cancer. Cancer Res 44:1735–1742
Sun Y, Campisi J, Higano C, Beer TM, Porter P, Coleman I, True L, Nelson PS (2012) Treatment-induced damage to the tumor microenvironment promotes prostate cancer therapy resistance through WNT16B. Nat Med 18:1359–1368
Swift RJ, Wirkus SA (2006) A course in ordinary differential equations. Chapman and Hall/CRC, Boca Raton
Tsygvintsev A, Marino S, Kirschner DE (2013) Mathematical model of gene therapy for the treatment of cancer. In: Ledzewicz U, Schättler H, Friedman A, Kashdan E (eds) Mathematical methods and models in biomedicine. Lecture notes on mathematical modelling in the life sciences. Springer, New York, NY, pp 367–385
Acknowledgements
We are very grateful to the editor in chief of the journal “Acta Biotheoretica”, and the anonymous reviewers for their useful remarks and constructive suggestions that improve substantially the manuscript.
Author information
Authors and Affiliations
Corresponding author
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Appendix
Appendix
In this section we present some concepts of viability theory involved in this paper, further developments can be found in Aubin (1990) and Aubin and Frankowska (1990).
Let \(f:{\mathbb {R}}^n\times {\mathbb {R}}^p\rightarrow {\mathbb {R}}^n\) a continuous function, we consider the following constrained controlled dynamical system:
where \(y:[0,+\infty [\rightarrow {\mathbb {R}}^n\) is an absolutely continuous function, \(u:{\mathbb {R}}^n\rightarrow {\mathcal {U}}\) is a continuous feedback control function and \({\mathcal {U}}\subset {\mathbb {R}}^p\) is a compact convex set.
Note that the system (25) can be rewritten by considering
G is continuous since f(., .) and u(.) are continuous.
We consider hence the new system
The viability theory aims to study the existence of trajectories of system (26) that start in a subset \(K\subset {\mathbb {R}}^n\) and remain in it thereafter. Note that the viability property is characterized throughout the contingent cone (Bouligand cone) which can be expressed as follows.
Definition 2
Let \(K\subset {\mathbb {R}}^n\), and \(x\in K\). The Bouligand cone \(T_{K}(x)\) to K at x is defined by
We can now define rigorously the viability concept, see Aubin and Frankowska (1990).
Definition 3
Let \(K\subset {\mathbb {R}}^n\), and y(.) a solution of the system (26). We say that
y(.) is locally viable in K if there exists \(T>0\) such that
$$\begin{aligned} \forall \; t\in [0,T],\;\;\; y(t)\in K. \end{aligned}$$y(.) is globally viable in K (or is a viable trajectory in K) if
$$\begin{aligned} \forall \; t\in [0,+\infty [,\;\;\; y(t)\in K. \end{aligned}$$K enjoys a local viability property if for any initial state \(x_0\in K\), there exist \(T>0\) and a solution of differential equation (26) starting at \(x_0\) and locally viable in K on [0, T].
K enjoys a global viability property (or viability property) if for any initial state \(x_0\in K\), there exist a solution of differential equation (26) starting at \(x_0\) and globally viable in K.
The relationship between the contingent cone and viable trajectories is illustrated in Fig. 3. The contingent cones to a set K at \(x_0\), \(x_1\) and \(x_2\) respectively, are represented by cones with angles represented by dotted lines. We mention that if \(G(x_i)\in T_K(x_i)\) for \(i=0,\;1,\;2\), then the vector field at each point \(x_i\) for \(i=0,\;1,\;2\), is pointed inside the set K and hence the trajectory solution of the system (26) and crossing through this \(x_i\) is directed inside the set K in this point. So if \(G(x)\in T_K(x),\;\forall \;x\in K\) then the trajectory is entirely contained in K.
The following theorem derives sufficient conditions for viability property, see Aubin (1990) and Aubin and Frankowska (1990).
Theorem 3
(Nagumo) Suppose thatK is closed and G is continuous and fulfils a linear growth condition, that is, there exist\(\sigma ,\;c>0\) such that
If for all\(x \in K: \;\;\; G(x) \in T_{K}(x)\), thenK enjoys a viability property. In this case the setK is called a viability domain.
In the theorem the growth condition substitutes the condition that G(K) is bounded to assure the global viability as proved in Theorem 10.1.6 (set-valued map version) in Aubin and Frankowska (1990).
Since the contingent cone is important to provide conditions for viability, the computation of this tool is necessary. J. P. Aubin and H. Frankowska give a useful characterization of the contingent cone in case of a subset K defined by inequalities [see the example on page 123, Aubin and Frankowska (1990)]:
Lemma 3
Let\(g=(g_1,\ldots ,g_p):{\mathbb {R}}^n\longrightarrow {\mathbb {R}}^p\) be a continuous function and consider the subset K of constraints defined by the inequalities
and let\(I(x):=\{i=1,\ldots ,p| g_i(x)=0\}\). If g is differentiable and
then the contingent cone is given by
Now, if for all\(i=1,\ldots ,p\): \(g_i(x)>0\), then\(x\in \mathring{K}\), and
The last expression derives from the fact that when \(x\in \mathring{K}\), the interior of K, then all tangential directions starting from x are pointed inside the set K, which implies that the contingent cone of K at x is the space \({\mathbb {R}}^n\).
Another concept involved in this paper is set-valued analysis. We define a set-valued map \(\varGamma :{\mathbb {R}}^n\rightsquigarrow {\mathbb {R}}^n\) as a multifunction such that for all \(x\in {\mathbb {R}}^n\),
A selection of a set-valued map \(\varGamma\) is a single-valued map \(w:{\mathbb {R}}^n\rightarrow {\mathbb {R}}^n\) such that
According to assumptions on the multifunction \(\varGamma\) we can provide minimal, continuous, Lipshitz etc. selections of it.
In this context, instead of a differential equation, we define differential inclusion as follows:
So the condition \(G(x) \in T_{K}(x)\), for all \(x\in K\), in Theorem 3 on the viability property is adapted to differential inclusion by setting [see Theorem 10.1.6, Aubin and Frankowska (1990)]
This intersection is viewed by means of selections, i.e. there exists a selection w of \(\varGamma\) such that
Rights and permissions
About this article
Cite this article
Serhani, M., Essaadi, H., Kassara, K. et al. Control by Viability in a Chemotherapy Cancer Model. Acta Biotheor 67, 177–200 (2019). https://doi.org/10.1007/s10441-019-09344-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10441-019-09344-0